Versant Capital Management’s Biogen BIIB Stock Holding History

Versant Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$333K	Buy	1,539 +208	+16%	+$39.8K	0.03%	432
2026 Q1	$244K	Buy	1,331 +266	+25%	+$49K	0.02%	511
2025 Q4	$187K	Buy	1,065 +169	+19%	+$27.6K	0.02%	517
2025 Q3	$126K	Buy	896 +66	+8%	+$8.92K	0.02%	626
2025 Q2	$104K	Buy	830 +459	+124%	+$57.2K	0.02%	657
2025 Q1	$50.8K	Sell	371 -30	-7%	-$4.29K	0.01%	856
2024 Q4	$61.3K	Buy	401 +279	+229%	+$47.1K	0.01%	501
2024 Q3	$23.6K	Sell	122 -32	-21%	-$6.7K	0.01%	750
2024 Q2	$35.7K	Buy	154 +85	+123%	+$18.5K	0.01%	505
2024 Q1	$14.9K	Sell	69 -3	-4%	-$703	﹤0.01%	605
2023 Q4	$18.6K	Buy	72 +3	+4%	+$737	0.01%	523
2023 Q3	$17.7K	Sell	69 -13	-16%	-$3.48K	0.01%	520
2023 Q2	$23.4K	Buy	82 +13	+19%	+$3.87K	0.01%	458
2023 Q1	$19.2K	Hold	69	–	–	0.01%	503
2022 Q4	$19.1K	Hold	69	–	–	0.01%	461
2022 Q3	$18K	Sell	69 -3	-4%	-$637	0.01%	442
2022 Q2	$15K	Buy	72 +4	+6%	+$818	0.01%	513
2022 Q1	$14K	Sell	68 -7	-9%	-$1.52K	﹤0.01%	575
2021 Q4	$18K	Hold	75	–	–	0.01%	528
2021 Q3	$21K	Hold	75	–	–	0.01%	448
2021 Q2	$26K	Hold	75	–	–	0.01%	393
2021 Q1	$21K	Hold	75	–	–	0.01%	531
2020 Q4	$18K	Hold	75	–	–	0.01%	530
2020 Q3	$21K	Sell	75 -3	-4%	-$837	0.01%	409
2020 Q2	$20K	Sell	78 -8	-9%	-$2.4K	0.01%	412
2020 Q1	$27K	Hold	86	–	–	0.01%	290
2019 Q4	$25K	Sell	86 -11	-11%	-$3.05K	0.01%	388
2019 Q3	$22K	Sell	97 -28	-22%	-$6.52K	0.01%	428
2019 Q2	$29K	Sell	125 -28	-18%	-$6.46K	0.01%	343
2019 Q1	$36K	Buy	153 +3	+2%	+$945	0.02%	365
2018 Q4	$45K	Hold	150	–	–	0.02%	271
2018 Q3	$52K	Hold	150	–	–	0.02%	286
2018 Q2	$43K	Sell	150 -2	-1%	-$562	0.02%	345
2018 Q1	$41K	Sell	152 -19	-11%	-$5.9K	0.02%	354
2017 Q4	$54K	Sell	171 -1	-0.6%	-$321	0.02%	284
2017 Q3	$53K	Sell	172 -59	-26%	-$17.5K	0.03%	244
2017 Q2	$62K	Sell	231 -10	-4%	-$2.64K	0.03%	208
2017 Q1	$65K	Sell	241 -10	-4%	-$2.83K	0.04%	199
2016 Q4	$71K	Sell	251 -20	-7%	-$5.93K	0.04%	188
2016 Q3	$84K	Buy	271 +8	+3%	+$2.37K	0.05%	158
2016 Q2	$63K	Hold	263	–	–	0.04%	192
2016 Q1	$68K	Sell	263 -10	-4%	-$2.64K	0.04%	171
2015 Q4	$83K	Buy	+273	New	+$78.4K	0.05%	145

Other funds holding BIIB

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

QCM

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

CIM

Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return

GIC

Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

ASR Vermogensbeheer Utrecht, Netherlands $9.71B AUM 37.32% 1-Year Est. Return

Versant Capital Management's BIIB Position: Q2 2026 in Review

Versant Capital Management increased its Biogen (BIIB) stake by 16% in Q2 2026, buying an estimated $39.8K and bringing the position to 1,539 shares worth $333K. The position accounts for 0.03% of the portfolio, ranked #432.

Versant Capital Management first reported a position in BIIB in Q4 2015 and has held it in 43 quarters since. 180 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Versant Capital Management held 1,539 shares of Biogen worth $333K as of Q2 2026.
Versant Capital Management bought 208 Biogen shares in Q2 2026, an estimated $39.8K.
Biogen made up 0.03% of Versant Capital Management's portfolio in Q2 2026, its #432 holding.
Versant Capital Management first reported a position in Biogen in Q4 2015 and has held it in 43 quarters since.
180 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.